aaiPharma (Nasdaq: AAII) has received FDA approval for its Multi-Vitamin Infusion (MVI) Adult Pharmacy Bulk Package.

The Wilmington-based company previously reported the FDA’s approval of a related New Drug Application (NDA) regarding the single-dose and univial presentations of MVI Adult on Jan. 30.

“We are very pleased with the approval of both NDAs for M.V.I. Adult,” said aaiPharma President and CEO Philip Tabbiner. “With these product approvals, aaiPharma will now be able to offer the most comprehensive, reformulated, low aluminum, infusion multivitamin product line to the market.

With the FDA approval, aaiPharma says the conditions for its contingent payment due to AstraZeneca have been met and, as previously guided, the company will make a third quarter payment of $31.5 million as the remainder of the purchase price MVI.

Shares of AAII were up 2 percent to around $19 in midday trading on the Nasdaq. Volume was half the normal amount.

aaiPharma: www.aaipharma.com